导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 2.78% | 1512/4773 |
| 近一周 | -2.54% | 2502/5462 |
| 近一月 | -5.09% | 3053/5421 |
| 近一季 | -8.86% | 2993/5209 |
| 近半年 | -6.65% | 3119/4920 |
| 近一年 | 7.71% | 1270/4366 |
| 近两年 | 73.14% | 916/2954 |
| 近三年 | 38.19% | 769/2253 |
| 成立以来 | 82.65% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
1.82% 1168/4961 |
19.17% 1316/5312 |
- - |
- - |
| 2025 | 31.56% 1229/4813 |
2.13% 1461/3635 |
2.08% 1885/4076 |
24.95% 1420/4524 |
1.00% 1609/4813 |
| 2024 | 7.45% 1657/3463 |
-2.34% 1351/2808 |
-5.19% 1667/3014 |
16.75% 1360/3129 |
-0.60% 1478/3463 |
| 2023 | -6.05% 808/2656 |
8.03% 502/2280 |
-4.34% 1142/2385 |
-4.63% 1188/2515 |
-4.67% 1137/2655 |
| 2022 | -17.95% 644/2207 |
-13.42% 756/1919 |
3.03% 1228/2016 |
-10.58% 428/2113 |
2.87% 814/2208 |
| 2021 | 18.09% 217/1822 |
-1.44% 492/1255 |
10.07% 493/1330 |
4.93% 309/1466 |
3.74% 396/1822 |
| 2020 | 22.86% 664/1250 |
-3.40% 300/1028 |
16.46% 437/1067 |
6.23% 864/1164 |
2.80% 965/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 国联中证500ETF VS. 长安沪深300非周期A(740101) |